

ESMO PRECEPTORSHIP PROGRAMME

Advanced non resectable hepatocellular carcinoma, biliary and pancreatic cancer

Singapore
18-19 November 2020

CO-CHAIRS: Ann-Lii Cheng, Taiwan
Konstantinos Kamposioras, United Kingdom

SPEAKERS: Ming-Chu Chang, Taiwan
Bang-Bin Chen, Taiwan
Eui Kyu Chie, South Korea
Su-Pin Choo, Singapore
Pierce Chow, Singapore
Apoorva Gogna, Singapore
Hiroshi Imaoka, Japan
Angela Lamarca, United Kingdom
Tony H.-K. Liang, Taiwan
Valérie Paradis, France
Julien Taieb, France

LEARNING OBJECTIVES

- To understand epidemiology, aetiology and molecular biology of hepatocellular carcinoma (HCC), biliary and pancreatic cancers
- To understand multidisciplinary management and treatment of advanced non resectable hepatocellular carcinoma, biliary and pancreatic cancers
- To learn about advances in the treatment and novel targets in hepatobiliary (HPB) carcinomas
- To address complex cases management frequently encountered in daily practice, related with these diseases
- To share experience across different health systems and clinical settings

Wednesday, 18 November

9:00-9:20 20'	Welcome and introduction	Ann-Lii Cheng, TW Konstantinos Kamposioras, UK
9:20-11:00 100'	SESSION 1 HCC	Co-Chairs: Pierce Chow, SG Ann-Lii Cheng, TW
30'	Epidemiology and pathology of HCC	Valérie Paradis, FR
40'	Systemic treatment of HCC in the era of immunotherapy. Paradigm shift and future directions in unresectable HCC	Ann-Lii Cheng, TW
30'	Locoregional treatment of unresectable HCC	Pierce Chow, SG

11:00-11:30	Coffee break	
11:30-13:10 125'	SESSION 2 Biliary tract cancers (BTC)	Chair: Konstantinos Kamposioras, UK
25'	First-line treatment in advanced BTCs and the continuum of care	Angela Lamarca, UK
25'	Molecular classification of BTCs and clinical relevance	Valérie Paradis, FR
25'	Future directions in the management of advanced BTCs	Angela Lamarca, UK
25'	The role of radiological techniques in advanced BTCs ; Focus on RT and SBRT	Eui Kyu Chie, KR
25'	The role of radiological techniques in advanced BTCs ; Focus on RFA, microwave ablation and cryotherapy	Apoorva Gogna, SG
13:35-14:30	Lunch	
14:30-15:15 45'	SESSION 3 Participants clinical case discussion	Co-Chairs: Ann-Lii Cheng, TW Konstantinos Kamposioras, UK
45'	Participants clinical case discussion (3x15')	Faculty
15:15-17:30 105'	SESSION 4 Transversal topics for advanced HPB malignancies	Chair: Konstantinos Kamposioras, UK
25'	The role of endoscopy in HPB cancers: From diagnosis to palliation	Hiroshi Imaoka, JP
25'	The evolving role of Proton Therapy in HPB cancer management	Tony H.-K. Liang, TW
15:45-16:15	Coffee break	
25'	Chemotherapy for difficult cases (jaundice and liver failure, solid organ transplantation, HBV, HCV infection)	Konstantinos Kamposioras, UK
30'	Participants clinical case discussion (2x15')	Faculty
17:30-18:10 40'	SPECIAL LECTURE	Chair: Ann-Lii Cheng, TW
40'	Management of immunotherapy-related adverse events in HPB cancer	Su-Pin Choo, SG
19:30	Dinner	

Thursday, 19 November

8:30-10:10 100'	SESSION 5 Pancreatic cancer – part I	Chair: Ann-Lii Cheng, TW
25'	Epidemiology, molecular characterisation and hereditary forms of pancreatic cancer	Ming-Chu Chang, TW
25'	Upfront radiologic staging and restaging assessment	Bang-Bin Chen, TW
25'	Locally advanced pancreatic cancer (LAPC): to palliate or to cure?	Julien Taieb, FR
25'	The role of RT in non resectable pancreatic cancer	Eui Kyu Chie, KR
10:10-10:40	Coffee break	

10:40-12:40 120'	SESSION 6 Pancreatic cancer – part II	Chair: Konstantinos Kamposioras, UK
40'	Systemic treatment of metastatic pancreatic cancer: From first-line treatment to second-line and beyond	Julien Taieb, FR or TBD
25'	Ongoing research and perspectives in advanced pancreatic cancer	Julien Taieb, FR or Konstantinos Kamposioras, UK
25'	Supportive care in pancreatic and HPB malignancies	Angela Lamarca, UK
30'	Participants clinical case discussion (2x15')	Faculty
12:40-13:00 20'	Conclusion and farewell	Co-Chairs: Ann-Lii Cheng, TW Konstantinos Kamposioras, UK
13:00-14:00	Lunch	

Note: Each 15' minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion